Novelix Pharmaceuticals has signed a Technology Transfer agreement with GMBU e.V., Germany, marking a strategic collaboration to advance the large-scale production of Astaxanthin, a potent antioxidant with broad nutraceutical and pharmaceutical applications.
Under the agreement, GMBU e.V. will transfer its proprietary technology, expertise, and technical support services for the cultivation and scale-up of Haematococcus pluvialis to Novelix’s state-of-the-art laboratories at BTIC Park, Genome Valley, Hyderabad. The collaboration aims to bring Astaxanthin to market at a commercial scale for global supply.
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program, including the provision of algal strains, media components, laboratory equipment, and infrastructure. The company will also establish a GMP-certified production facility at its Techno Park site in Hyderabad to manufacture Astaxanthin in bulk, targeting key markets across Europe, North America, and India.
Novelix Pharmaceuticals is an innovation-driven biopharmaceutical company based in Hyderabad, India, focused on novel therapeutics, advanced biologics, and nutraceutical research.
